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26 Cystic ﬁbrosis transmembrane conductance regulator (CFTR)
gene sequence variation in Portuguese infertile males
P. Pacheco1, P. Loureiro1, C. Silva1. 1Instituto Nacional de Sau´de Dr. Ricardo
Jorge, Gene´tica Humana, Lisboa, Portugal
Objectives: Obstructive azoospermia is present in the greatest majority of male
patients with Cystic Fibrosis (CF), mainly because of congenital bilateral absence
of the vas deferens (CBAVD). The aim of this study was to identify the presence
of CFTR gene mutations in Portuguese adult infertile males, clinically diagnosed
with CBAVD, CUAVD, azoospermia and other clinical reasons of infertility.
Methods: The CFTR gene analysis was performed in 105 patients, using ARMS-
Ampliﬁcation Refractory Mutation System, RDB-Reverse Dot-Blot (INNO-LiPA
CFTR19 and 17+Tn update), DGGE-Denaturing Gradient Gel Electrophoresis) and
DNA sequencing, detecting about 93% of the mutations associated to CF in the
Portuguese population.
Conclusion: In the group of patients clinically diagnosed with CBAVD/CUAVD/
Azoospermia (82/105): CFTR mutations were found in 60% (2 mutations in 33%
and 1 mutation in 27%).
The most frequent CF mutation was c.1521_1523delCTT (F508del) in 32% of
the patients and the poly-T variation c.1210−12T[5] (IVS8−6(5T)) was found
in 40%. The most frequent genotype was c.[1521_1523delCTT];[1210−12T[5]]
(F508del/IVS8−6(5T)) present in 23% of the patients.
In the remaining infertile patients (23/105) the frequency of CFTR mutations was
similar to the general population. Although the clinical diagnosis is not very speciﬁc,
we were able to detect a high frequency of CF carriers. It’s important to analyze
these men in assisted reproduction programs to prevent new cases of CF.
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Introduction: From July 1, 2007 to January 1, 2012 all newly diagnosed CF patients
in the Netherlands were registered by the Dutch Pediatric Surveillance Unit (DPSU).
Newborn screening for CF (NBSCF) was performed from January 2008 during a
study of two new screening strategies in 4 provinces. From May 1, 2011 NBSCF
was added to the Dutch routine newborn screening program.
Objectives: To assess inﬂuence of NBSCF on state of disease at the time of
diagnosis.
Methods: All children diagnosed with CF and reported to the DPSU between July
2007 and January 2012 were included in the study. State of disease was assessed
by questionnaires sent to the attending paediatricians.
Results: In total there were 204 reports of CF. In 179 CF was conﬁrmed. 133
questionnaires were returned. 90 patients were diagnosed clinically, 34 by neonatal
screening, 3 otherwise. In 6 the way of diagnosis was unclear. Median age
at diagnosis was 31.5 weeks (IQR 8.25–106.75) for a clinical diagnosis resp.
3.6 weeks (IQR 3.0−4.0) for neonatal screening. Children diagnosed clinically had
signiﬁcantly more growth retardation for height and weight (p< 0.05), steatorrhoea
(p< 0.001) or recurrent pulmonary problems (42.5%) at the time of diagnosis than
children diagnosed by screening (0%).
Conclusion: Growth retardation is present in most children diagnosed clinically
and many have chronic pulmonary problems at the time of diagnosis. Newborn
screening offers the opportunity to start treatment before growth retardation or
pulmonary problems have arisen.
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Objectives: Since May 2011 newborn screening for CF (NBSCF) has been added
to the Dutch routine screening program. Aim of study: to evaluate performance and
effectivity of NBSCF in the Netherlands.
Methods: All newborns included in the Dutch routine heel prick program were
screened for CF by a 4-step screening strategy, IRT/PAP/DNA/extended gene
analysis (EGA). NBSCF was positive only when 2 CF mutations were identiﬁed. As
fail-safe procedure EGA was performed on all samples with IRT >100mg/l without
CF-mutations.
From May 2011 to October 2012 256,008 newborns were screened for CF. PAP
concentrations >cut-off point were found in 345 of 2969 samples (1.25%) with
IRT >60mg/l. Subsequent DNA-analysis found 2 CF-mutations in 47, and one
mutation in 29 samples. In these 29 samples, EGA revealed a second mutation in
10, resulting in 57 babies with a positive screen for CF (1: 4491), and 14 carriers of
one clinically relevant CF-mutation (1:18285). CF was conﬁrmed in 47 newborns,
10 babies had non-classical CF with equivocal (n = 4) or normal sweat tests; this
resulted in a PPV of 85% for classical CF. Nine babies had meconium-ileus (MI), of
which 1 was missed by screening. The failsafe procedure identiﬁed no CF-patients.
So far, 2 babies without MI were missed by screening, resulting in a sensitivity of
the program of 95%. In 2011 treatment in a CF centre was started within the ﬁrst
month of life in 85% of the identiﬁed patients.
Conclusion: The IRT/PAP/DNA/EGA strategy applied in a large birth cohort leads
to an early CF diagnosis and treatment, shows a high PPV of 85% and an acceptable
sensitivity of 95%, conﬁrming earlier ﬁndings (Thorax 2012;67,289−95).
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Newborn Screening programmes will identify infants with an equivocal diagnosis of
CF. The absence of guidelines for management of these infants presents CF teams
with the challenge of monitoring their progress without medicalisation of the
child. Since 2007 we have screened 29,000 infants p.a. with an IRT-DNA-IRT
protocol. Of 109 positive referrals 86 have a diagnosis of CF with 11 having an
equivocal diagnosis [1] and are 14−52 months post diagnosis. We reviewed the
genotype, pancreatic function, nutritional parameters, treatment, clinic attendances,
microbiology, radiology, hospital admissions and compliance with the guidance
from the European consensus on the management of these infants [1]. 10/11 had 2
CF genes at referral. All had normal pancreatic function and are thriving. All have
had a prophylactic antibiotic and were given standard advice on smoking and ﬂu
vaccination. They have been seen routinely in a multidisciplinary CF clinic, had CF
Annual Review and been reviewed yearly by the regional specialist CF team. Staph.
aureus was isolated in 3/11 and pseud.aeruginosa in 4/11 and treated routinely (2/4
had IV therapy). Chest x-rays are normal. The parents have agreed to data entry on
the UK CF registry. Compliance with the guidance from the European consensus
has been variable. These infants account for >10% of those diagnosed following
NBS in our network and their clinical management has not differed from other
CF patients. Parent’s perception of the value of routine follow up in this group
should be sought. A national review of the management of these children could
inform a UK management protocol supporting CF teams in their delivery of care.
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